Last reviewed · How we verify
IV N-Acetyl Cystein
N-Acetyl Cysteine (NAC) replenishes intracellular glutathione and acts as a potent antioxidant to reduce oxidative stress and inflammation.
N-Acetyl Cysteine (NAC) replenishes intracellular glutathione and acts as a potent antioxidant to reduce oxidative stress and inflammation. Used for Acetaminophen (paracetamol) overdose and hepatotoxicity prevention, Acute respiratory distress syndrome (ARDS), Chronic obstructive pulmonary disease (COPD) exacerbations.
At a glance
| Generic name | IV N-Acetyl Cystein |
|---|---|
| Sponsor | Imam Khomeini Hospital |
| Drug class | Antioxidant / Mucolytic agent |
| Target | Glutathione synthesis pathway; free radicals and reactive oxygen species |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Respiratory / Toxicology |
| Phase | Phase 3 |
Mechanism of action
NAC is a precursor to the tripeptide glutathione, a major cellular antioxidant that neutralizes reactive oxygen species and free radicals. By restoring depleted glutathione pools, NAC protects cells from oxidative damage, reduces inflammatory cytokine production, and may enhance mucosal and tissue repair. IV administration provides rapid systemic bioavailability for acute conditions where oral absorption is insufficient.
Approved indications
- Acetaminophen (paracetamol) overdose and hepatotoxicity prevention
- Acute respiratory distress syndrome (ARDS)
- Chronic obstructive pulmonary disease (COPD) exacerbations
- Cystic fibrosis
Common side effects
- Nausea and vomiting
- Flushing and facial erythema
- Anaphylactoid reactions
- Rash and pruritus
- Bronchospasm
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV N-Acetyl Cystein CI brief — competitive landscape report
- IV N-Acetyl Cystein updates RSS · CI watch RSS
- Imam Khomeini Hospital portfolio CI